Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $105 at Leerink Partners
October 30, 2024 6:26 AM EDTLeerink Partners analyst Joseph Schwartz lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $105.00 (from $132.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: This time last year on the 3Q23 earnings conference call, former CEO Jean Jacques (JJ) Bienaimé publicized his retirement (effective December 1, 2023) and Alexander Hardy who was the CEO of Genentech at Roche (RHHBY, Not Rated) at... More
